Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection

Detalhes bibliográficos
Autor(a) principal: Silva, Kelly Maria Rêgo da
Data de Publicação: 2021
Outros Autores: Silva, Pryscilla Bizerra da, Silva, Higo José Neri da, Silva, Pauliana Texeira da, Silva, Bruna Layra, Ferreira, Ana Maria Castro, Bezerra, Wallyson André dos Santos, Silva, Denilson de Araújo e, Campos, Mariel Rodrigues de, Oliveira, Deylane Menezes Teles e, Nascimento, Antonia Luzia Lima do, Ribeiro, Alice Maria de Castro, Silva, Amanda Miranda da, Sousa, Emille Andrade, Oliveira, Iara Katrynne Fonsêca, Lopes, Michelle Maria Ferreira, Andrade, Nathália Batista de, Pinheiro, Iluska Martins, Ferreira, Kivia Ludmilla Carvalho, Furtado, Denis Romulo Leite
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/13136
Resumo: Coronaviruses are viruses that cause respiratory infections that can affect animals and humans. The SARS-CoV-2 epidemic, which caused COVID-19, began in Wuhan (China) in December 2019, and spread to several countries, becoming a dangerous pandemic without specific treatment. This work aims to show cases treated with the main drugs for SARS-CoV-2, evaluating its efficacy and disadvantages. Publications with data from pharmacological treatments for the new SARS-CoV-2, scientific publications, world health organization (WHO) and governmental publications were used, among the date (2019-2020). Data were collected from the following scientific databases: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Virtual Health Library - VHL, SCIELO, Cochrane Library, HighWire Press, Scopus and Elsevier; and the technological bases: WIPO and PTO. The use of these drugs may have led to improvement and cure of patients globally. They are believed to be effective against the disease. However, we need scientific proofs. In the results we observed the drugs used worldwide and the patents approved until (15/09/2020). There is no treatment for Covid19, medications that soften the flu-like symptoms of the disease were used. In emergency cases, the combination of the antibiotic azithromycin and hydroxychloroquine, used for malaria and other medicines, was used. This study evaluated most of the drugs that are in use for the treatment of SARS-CoV-2, in order to present a drug or more that is effective for the treatment of the disease, also showing whether in vitro and in vivo research was conducted in the search for a better treatment.
id UNIFEI_3076e2be565b8e5ce6387a872cb3ebe2
oai_identifier_str oai:ojs.pkp.sfu.ca:article/13136
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection Evaluación de los principales farmacoses utilizados para sars-cov-2: una prospección científica y tecnológica Avaliação dos principais fármacos utilizados para o sars-cov-2: uma prospecção cientifica e tecnológicaCovid-19CoronavírusSARS-CoV-2.CoronavirusCovid-19SARS-CoV-2.Coronavirus Covid-19SARS-CoV-2.Coronaviruses are viruses that cause respiratory infections that can affect animals and humans. The SARS-CoV-2 epidemic, which caused COVID-19, began in Wuhan (China) in December 2019, and spread to several countries, becoming a dangerous pandemic without specific treatment. This work aims to show cases treated with the main drugs for SARS-CoV-2, evaluating its efficacy and disadvantages. Publications with data from pharmacological treatments for the new SARS-CoV-2, scientific publications, world health organization (WHO) and governmental publications were used, among the date (2019-2020). Data were collected from the following scientific databases: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Virtual Health Library - VHL, SCIELO, Cochrane Library, HighWire Press, Scopus and Elsevier; and the technological bases: WIPO and PTO. The use of these drugs may have led to improvement and cure of patients globally. They are believed to be effective against the disease. However, we need scientific proofs. In the results we observed the drugs used worldwide and the patents approved until (15/09/2020). There is no treatment for Covid19, medications that soften the flu-like symptoms of the disease were used. In emergency cases, the combination of the antibiotic azithromycin and hydroxychloroquine, used for malaria and other medicines, was used. This study evaluated most of the drugs that are in use for the treatment of SARS-CoV-2, in order to present a drug or more that is effective for the treatment of the disease, also showing whether in vitro and in vivo research was conducted in the search for a better treatment.Coronaviruses are viruses that cause respiratory infections that can affect animals and humans. The SARS-CoV-2 epidemic, which caused COVID-19, began in Wuhan (China) in December 2019, and spread to several countries, becoming a dangerous pandemic without specific treatment. This work aims to show cases treated with the main drugs for SARS-CoV-2 evaluating its efficacy and disadvantages. Publications with data from pharmacological treatments for the new SARS-CoV-2, scientific publications, world health organization (WHO) and governmental publications were used, among the date (2019-2020). Data were collected from the following scientific databases: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Virtual Health Library - VHL, SCIELO, Cochrane Library, HighWire Press, Scopus and Elsevier; and the technological bases: WIPO and PTO. The use of these drugs may have led to improvement and cure of patients globally. They are believed to be effective against the disease. However, we need scientific proofs. In the results we observed the drugs used worldwide and the patents approved until (15/09/2020). Los coronavirus son virus que causan infecciones respiratorias que pueden afectar a animales y seres humanos. La epidemia del SARS-CoV-2, que causó covid-19, comenzó en Wuhan (China) en diciembre de 2019, y se extendió a varios países, convirtiéndose en una peligrosa pandemia sin tratamiento específico. Este trabajo tiene como objetivo mostrar los casos tratados con los principales fármacos para el SARS-CoV-2 evaluando su eficacia y desventajas. Entre la fecha (2019-2020) se utilizaron publicaciones con datos de tratamientos farmacológicos para el nuevo SARS-CoV-2, publicaciones científicas, organización mundial de la salud (OMS) y publicaciones gubernamentales.Os Coronavírus são vírus que causam infecções respiratórias podendo afetar animais e humanos. A epidemia de SARS-CoV-2, causador da COVID-19 teve início em Wuhan (China) em dezembro de 2019, e se espalhou por diversos países tornando-se uma pandemia perigosa e sem tratamento especifico. Esse trabalho pretende mostrar casos tratados com os principais fármacos para o SARS-CoV-2 avaliando sua eficácia e desvantagens. Foram utilizadas publicações com dados de tratamentos farmacológicos para o novo SARS-CoV-2, publicações cientificas, oficiais da Organização Mundial da Saúde (World Health Organization - WHO) e governamentais, dentre a data (2019-2020). Os dados foram coletados nas bases cientificas: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Biblioteca Virtual em saúde - BVS, SCIELO, Cochrane Library, HighWire Press, Scopus e Elsevier; e as bases tecnológicas: WIPO e INPI. A utilização desses fármacos pode ter ocasionado melhora e cura de pacientes globalmente. Acredita-se que são eficazes contra a doença. Porém, temos a necessidade de comprovações cientificas. Nos resultados observamos os fármacos utilizados mundialmente e as patentes aprovadas até (15/09/2020). Não existe tratamento para a Covid19, utilizou-se medicamentos amenizadores dos sintomas gripais da doença. Nos casos emergenciais foram utilizados a combinação do antibiótico azitromicina e hidroxicloroquina, usados para malária e outros medicamentos. Este trabalho avaliou grande parte dos medicamentos que estão em uso para o tratamento do SARS-CoV-2, com o intuito de apresentar um fármaco ou mais que seja eficaz para o tratamento da doença, mostrando ainda se foram realizadas pesquisas in vitro e in vivo na busca de uma melhor tratativa.Research, Society and Development2021-03-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1313610.33448/rsd-v10i3.13136Research, Society and Development; Vol. 10 No. 3; e19310313136Research, Society and Development; Vol. 10 Núm. 3; e19310313136Research, Society and Development; v. 10 n. 3; e193103131362525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/13136/11884Copyright (c) 2021 Kelly Maria Rêgo da Silva; Pryscilla Bizerra da Silva; Higo José Neri da Silva; Pauliana Texeira da Silva; Bruna Layra Silva; Ana Maria Castro Ferreira; Wallyson André dos Santos Bezerra; Denilson de Araújo e Silva; Mariel Rodrigues de Campos; Deylane Menezes Teles e Oliveira; Antonia Luzia Lima do Nascimento; Alice Maria de Castro Ribeiro; Amanda Miranda da Silva; Emille Andrade Sousa; Iara Katrynne Fonsêca Oliveira; Michelle Maria Ferreira Lopes; Nathália Batista de Andrade; Iluska Martins Pinheiro; Kivia Ludmilla Carvalho Ferreira; Denis Romulo Leite Furtadohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Kelly Maria Rêgo da Silva, Pryscilla Bizerra da Silva, Higo José Neri da Silva, Pauliana Texeira da Silva, Bruna Layra Ferreira, Ana Maria Castro Bezerra, Wallyson André dos Santos Silva, Denilson de Araújo e Campos, Mariel Rodrigues de Oliveira, Deylane Menezes Teles e Nascimento, Antonia Luzia Lima do Ribeiro, Alice Maria de Castro Silva, Amanda Miranda da Sousa, Emille Andrade Oliveira, Iara Katrynne Fonsêca Lopes, Michelle Maria Ferreira Andrade, Nathália Batista de Pinheiro, Iluska Martins Ferreira, Kivia Ludmilla Carvalho Furtado, Denis Romulo Leite 2021-03-28T12:03:35Zoai:ojs.pkp.sfu.ca:article/13136Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:34:33.110791Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection
Evaluación de los principales farmacoses utilizados para sars-cov-2: una prospección científica y tecnológica
Avaliação dos principais fármacos utilizados para o sars-cov-2: uma prospecção cientifica e tecnológica
title Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection
spellingShingle Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection
Silva, Kelly Maria Rêgo da
Covid-19
Coronavírus
SARS-CoV-2.
Coronavirus
Covid-19
SARS-CoV-2.
Coronavirus
Covid-19
SARS-CoV-2.
title_short Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection
title_full Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection
title_fullStr Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection
title_full_unstemmed Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection
title_sort Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection
author Silva, Kelly Maria Rêgo da
author_facet Silva, Kelly Maria Rêgo da
Silva, Pryscilla Bizerra da
Silva, Higo José Neri da
Silva, Pauliana Texeira da
Silva, Bruna Layra
Ferreira, Ana Maria Castro
Bezerra, Wallyson André dos Santos
Silva, Denilson de Araújo e
Campos, Mariel Rodrigues de
Oliveira, Deylane Menezes Teles e
Nascimento, Antonia Luzia Lima do
Ribeiro, Alice Maria de Castro
Silva, Amanda Miranda da
Sousa, Emille Andrade
Oliveira, Iara Katrynne Fonsêca
Lopes, Michelle Maria Ferreira
Andrade, Nathália Batista de
Pinheiro, Iluska Martins
Ferreira, Kivia Ludmilla Carvalho
Furtado, Denis Romulo Leite
author_role author
author2 Silva, Pryscilla Bizerra da
Silva, Higo José Neri da
Silva, Pauliana Texeira da
Silva, Bruna Layra
Ferreira, Ana Maria Castro
Bezerra, Wallyson André dos Santos
Silva, Denilson de Araújo e
Campos, Mariel Rodrigues de
Oliveira, Deylane Menezes Teles e
Nascimento, Antonia Luzia Lima do
Ribeiro, Alice Maria de Castro
Silva, Amanda Miranda da
Sousa, Emille Andrade
Oliveira, Iara Katrynne Fonsêca
Lopes, Michelle Maria Ferreira
Andrade, Nathália Batista de
Pinheiro, Iluska Martins
Ferreira, Kivia Ludmilla Carvalho
Furtado, Denis Romulo Leite
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, Kelly Maria Rêgo da
Silva, Pryscilla Bizerra da
Silva, Higo José Neri da
Silva, Pauliana Texeira da
Silva, Bruna Layra
Ferreira, Ana Maria Castro
Bezerra, Wallyson André dos Santos
Silva, Denilson de Araújo e
Campos, Mariel Rodrigues de
Oliveira, Deylane Menezes Teles e
Nascimento, Antonia Luzia Lima do
Ribeiro, Alice Maria de Castro
Silva, Amanda Miranda da
Sousa, Emille Andrade
Oliveira, Iara Katrynne Fonsêca
Lopes, Michelle Maria Ferreira
Andrade, Nathália Batista de
Pinheiro, Iluska Martins
Ferreira, Kivia Ludmilla Carvalho
Furtado, Denis Romulo Leite
dc.subject.por.fl_str_mv Covid-19
Coronavírus
SARS-CoV-2.
Coronavirus
Covid-19
SARS-CoV-2.
Coronavirus
Covid-19
SARS-CoV-2.
topic Covid-19
Coronavírus
SARS-CoV-2.
Coronavirus
Covid-19
SARS-CoV-2.
Coronavirus
Covid-19
SARS-CoV-2.
description Coronaviruses are viruses that cause respiratory infections that can affect animals and humans. The SARS-CoV-2 epidemic, which caused COVID-19, began in Wuhan (China) in December 2019, and spread to several countries, becoming a dangerous pandemic without specific treatment. This work aims to show cases treated with the main drugs for SARS-CoV-2, evaluating its efficacy and disadvantages. Publications with data from pharmacological treatments for the new SARS-CoV-2, scientific publications, world health organization (WHO) and governmental publications were used, among the date (2019-2020). Data were collected from the following scientific databases: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Virtual Health Library - VHL, SCIELO, Cochrane Library, HighWire Press, Scopus and Elsevier; and the technological bases: WIPO and PTO. The use of these drugs may have led to improvement and cure of patients globally. They are believed to be effective against the disease. However, we need scientific proofs. In the results we observed the drugs used worldwide and the patents approved until (15/09/2020). There is no treatment for Covid19, medications that soften the flu-like symptoms of the disease were used. In emergency cases, the combination of the antibiotic azithromycin and hydroxychloroquine, used for malaria and other medicines, was used. This study evaluated most of the drugs that are in use for the treatment of SARS-CoV-2, in order to present a drug or more that is effective for the treatment of the disease, also showing whether in vitro and in vivo research was conducted in the search for a better treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021-03-12
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/13136
10.33448/rsd-v10i3.13136
url https://rsdjournal.org/index.php/rsd/article/view/13136
identifier_str_mv 10.33448/rsd-v10i3.13136
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/13136/11884
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 3; e19310313136
Research, Society and Development; Vol. 10 Núm. 3; e19310313136
Research, Society and Development; v. 10 n. 3; e19310313136
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052746340237312